Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: Modulation by cannabinoids

Blood

Volumn 116, Issue 3, 2010, Pages 456-465

  Kohli, Divyanshoo R ^a   Li, Yunfang ^a   Khasabov, Sergey G ^b   Gupta, Pankaj ^a   Kehl, Lois J ^c   Ericson, Marna E ^b   Nguyen, Julia ^a   Gupta, Vinita ^d   Hebbel, Robert P ^a   Simone, Donald A ^b   Gupta, Kalpna ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Minnesota Head and Neck Pain Clinic   (United States)

^d BIO RAD LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CALCITONIN GENE RELATED PEPTIDE; CYCLOOXYGENASE 2; HEMOGLOBIN A; HEMOGLOBIN S; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MORPHINE SULFATE; MU OPIATE RECEPTOR; STAT3 PROTEIN; SUBSTANCE P; TOLL LIKE RECEPTOR 4; 3 (2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL) 4 (3 HYDROXYPROPYL)CYCLOHEXANOL; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; CANNABINOID; CANNABINOID RECEPTOR; CYCLOHEXANOL DERIVATIVE; MORPHINE; RECOMBINANT PROTEIN;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; COLD HYPERALGESIA; CONTROLLED STUDY; DEEP TISSUE HYPERALGESIA; ENZYME PHOSPHORYLATION; FEMALE; HEAT HYPERALGESIA; HYPERALGESIA; IMMUNOREACTIVITY; LYMPH VESSEL; MALE; MECHANICAL HYPERALGESIA; MOUSE; MUSCULOSKELETAL PAIN; NERVE CELL; NONHUMAN; PERIPHERAL NERVE; PERIPHERAL VASCULAR SYSTEM; PINCH STRENGTH; PRIORITY JOURNAL; SKIN BLOOD VESSEL; SPINAL CORD; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; GENETICS; GLIA; HUMAN; INNERVATION; METABOLISM; MOUSE MUTANT; PAIN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; SICKLE CELL ANEMIA; SKIN; TRANSGENIC MOUSE; VASCULARIZATION;

ANEMIA, SICKLE CELL; ANIMALS; BEHAVIOR, ANIMAL; CALCITONIN GENE-RELATED PEPTIDE; CANNABINOIDS; CYCLOHEXANOLS; DISEASE MODELS, ANIMAL; FEMALE; HEMOGLOBIN, SICKLE; HUMANS; HYPERALGESIA; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MORPHINE; NEUROGLIA; PAIN; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID, MU; RECOMBINANT PROTEINS; SKIN; SPINAL CORD; SUBSTANCE P;

EID: 77955891248     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-260372     Document Type: Article

References (44)

1. Ballas SK. Progress in Pain Research and Management; vol 11. Seattle, WA: IASP Press; 1998.
2. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94-101. (Pubitemid 351651552)
3. Ballas SK. Current issues in sickle cell pain and its management. Hematology Am Soc Hematol Educ Program. 2007:97-105.
4. Dampier CD, Setty BN, Logan J, Ioli JG, Dean R. Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. J Pediatr. 1995;126(3):461-467.
5. Darbari DS, Minniti CP, Rana S, van den Anker J. Pharmacogenetics of morphine: potential implications in sickle cell disease. Am J Hematol. 2008;83(3):233-236. (Pubitemid 351303949)
6. Nagar S, Remmel RP, Hebbel RP, Zimmerman CL. Metabolism of opioids is altered in liver microsomes of sickle cell transgenic mice. Drug Metab Dispos. 2004;32(1):98-104. (Pubitemid 38112541)
7. Kopecky EA, Jacobson S, Joshi P, Koren G. Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease. Clin Pharmacol Ther. 2004;75(3):140-146. (Pubitemid 38324540)
8. Weber ML, Farooqui M, Nguyen J, et al. Morphine induces mesangial cell proliferation and glomerulopathy via kappa-opioid receptors. Am J Physiol Renal Physiol. 2008;294(6):F1388-F1397.
9. Khasabova IA, Khasabov SG, Harding-Rose C, et al. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci. 2008;28(44):11141- 11152.
10. Cheng Y, Hitchcock SA. Targeting cannabinoid agonists for inflammatory and neuropathic pain. Expert Opin Investig Drugs. 2007;16(7):951-965. (Pubitemid 47074154)
11. Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009;60(1):255-266.
12. Elikkottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids. J Opioid Manag. 2009;5(6):341-357.
13. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167-179.
14. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29(9):2068-2079.
15. Watkins LR, Hutchinson MR, Milligan ED, Maier SF. "Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. Brain Res Rev. 2007;56(1):148-169.
16. Li D, Ren Y, Xu X, Zou X, Fang L, Lin Q. Sensitization of primary afferent nociceptors induced by intradermal capsaicin involves the peripheral release of calcitonin gene-related peptide driven by dorsal root reflexes. J Pain. 2008;9(12):1155-1168.
17. Manci EA, Hillery CA, Bodian CA, Zhang ZG, Lutty GA, Coller BS. Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. Blood. 2006;107(4):1651-1658.
18. Solovey A, Kollander R, Shet A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood. 2004;104(3):840-846. (Pubitemid 38970583)
19. Lunzer MM, Yekkirala A, Hebbel RP, Portoghese PS. Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia. Proc Natl Acad Sci U S A. 2007;104(14):6061-6065. (Pubitemid 47175658)
20. Pászty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278(5339):876-878. (Pubitemid 27467927)
21. Noguchi CT, Gladwin M, Diwan B, et al. Pathophysiology of a sickle cell trait mouse model: human alpha(beta)(S) transgenes with one mouse beta-globin allele. Blood Cells Mol Dis. 2001;27(6):971-977. (Pubitemid 34163965)
22. Lynch JL, Gallus NJ, Ericson ME, Beitz AJ. Analysis of nociception, sex and peripheral nerve innervation in the TMEV animal model of multiple sclerosis. Pain. 2008;136(3):293-304.
23. Tapocik JD, Letwin N, Mayo CL, et al. Identification of candidate genes and gene networks specifically associated with analgesic tolerance to morphine. J Neurosci. 2009;29(16):5295-5307.
24. Ishikawa K, McGaugh JL, Shibanoki S, Kubo T. A sensitive procedure for determination of morphine in mouse whole blood by high performance liquid chromatography with electrochemical detection. Jpn J Pharmacol. 1982;32(5):969-971. (Pubitemid 12030653)
25. Poonawala T, Levay-Young BK, Hebbel RP, Gupta K. Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005;13(2):165-174. (Pubitemid 40489866)
26. Smith WR, Bauserman RL, Ballas SK, et al. Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea. Pain. 2009;146(1):91-98.
27. Westerman MP, Bailey K, Freels S, Schlegel R, Williamson P. Assessment of painful episode frequency in sickle-cell disease. Am J Hematol. 1997;54(3):183-188. (Pubitemid 27148255)
28. Serjeant GR, Chalmers RM. Current concerns in haematology: 1. Is the painful crisis of sickle cell disease a "steal" syndrome? J Clin Pathol. 1990;43(10):789-791.
29. Mohan J, Marshall JM. A comparative study in subjects with homozygous sickle cell disease and in normal subjects of responses evoked in forearm vasculature by mild, indirect cooling. Clin Auton Res. 1994;4(1):35-40. (Pubitemid 24157816)
30. Ejindu VC, Hine AL, Mashayekhi M, Shorvon PJ, Misra RR. Musculoskeletal manifestations of sickle cell disease. Radiographics. 2007;27(4):1005-1021.
31. Jain R, Sawhney S, Rizvi SG. Acute bone crises in sickle cell disease: the T1 fat-saturated sequence in differentiation of acute bone infarcts from acute osteomyelitis. Clin Radiol. 2008;63(1):59-70. (Pubitemid 350212867)
32. Franck LS, Treadwell M, Jacob E, Vichinsky E. Assessment of sickle cell pain in children and young adults using the adolescent pediatric pain tool. J Pain Symptom Manage. 2002;23(2):114-120. (Pubitemid 34158643)
33. Sporrer KA, Jackson SM, Agner S, Laver J, Abboud MR. Pain in children and adolescents with sickle cell anemia: a prospective study utilizing self-reporting. Am J Pediatr Hematol Oncol. 1994;16(3):219-224. (Pubitemid 24223770)
34. Ballet S, Conrath M, Fischer J, Kaneko T, Hamon M, Cesselin F. Expression and G-protein coupling of mu-opioid receptors in the spinal cord and dorsal root ganglia of polyarthritic rats. Neuropeptides. 2003;37(4):211-219. (Pubitemid 37041013)
35. Hamamoto DT, Giridharagopalan S, Simone DA. Acute and chronic administration of the cannabinoid receptor agonist CP 55940 attenuates tumor-evoked hyperalgesia. Eur J Pharmacol. 2007;558(1):73-87. (Pubitemid 46328873)
36. Howard J, Anie KA, Holdcroft A, Korn S, Davies SC. Cannabis use in sickle cell disease: a questionnaire study. Br J Haematol. 2005;131(1):123-128. (Pubitemid 43899717)
37. Potenzieri C, Brink TS, Pacharinsak C, Simone DA. Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation. J Neurophysiol. 2008;100(5):2794-2806.
38. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008;153(2):319-334.
39. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11(2):129-151. (Pubitemid 39619075)
40. Belcher JD, Bryant CJ, Nguyen J, et al. Transgenic sickle mice have vascular inflammation. Blood. 2003;101(10):3953-3959. (Pubitemid 36857872)
41. Bigliardi-Qi M, Gaveriaux-Ruff C, Pfaltz K, et al. Deletion of mu- and kappa-opioid receptors in mice changes epidermal hypertrophy, density of peripheral nerve endings, and itch behavior. J Invest Dermatol. 2007;127(6):1479-1488. (Pubitemid 46762967)
42. Li Y, Hsieh ST, Chien HF, Zhang X, McArthur JC, Griffin JW. Sensory and motor denervation influence epidermal thickness in rat foot glabrous skin. Exp Neurol. 1997;147(2):452-462. (Pubitemid 27497306)
43. Almarestani L, Longo G, Ribeiro-da-Silva A. Autonomic fiber sprouting in the skin in chronic inflammation. Mol Pain. 2008;4:56.
44. Honore P, Rogers SD, Schwei MJ, et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience. 2000;98(3):585-598. (Pubitemid 30408178)